Literature DB >> 20110423

Structure and function of factor XI.

Jonas Emsley1, Paul A McEwan, David Gailani.   

Abstract

Factor XI (FXI) is the zymogen of an enzyme (FXIa) that contributes to hemostasis by activating factor IX. Although bleeding associated with FXI deficiency is relatively mild, there has been resurgence of interest in FXI because of studies indicating it makes contributions to thrombosis and other processes associated with dysregulated coagulation. FXI is an unusual dimeric protease, with structural features that distinguish it from vitamin K-dependent coagulation proteases. The recent availability of crystal structures for zymogen FXI and the FXIa catalytic domain have enhanced our understanding of structure-function relationships for this molecule. FXI contains 4 "apple domains" that form a disk structure with extensive interfaces at the base of the catalytic domain. The characterization of the apple disk structure, and its relationship to the catalytic domain, have provided new insight into the mechanism of FXI activation, the interaction of FXIa with the substrate factor IX, and the binding of FXI to platelets. Analyses of missense mutations associated with FXI deficiency have provided additional clues to localization of ligand-binding sites on the protein surface. Together, these data will facilitate efforts to understand the physiology and pathology of this unusual protease, and development of therapeutics to treat thrombotic disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110423      PMCID: PMC4828079          DOI: 10.1182/blood-2009-09-199182

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  104 in total

1.  Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation.

Authors:  Dharmaraj Samuel; Hong Cheng; Paul W Riley; Adrian A Canutescu; Chandrasekaran Nagaswami; John W Weisel; Zimei Bu; Peter N Walsh; Heinrich Roder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

2.  Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.

Authors:  Lei Jin; Pramod Pandey; Robert E Babine; David T Weaver; Sherin S Abdel-Meguid; James E Strickler
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-09-28

3.  Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H- and 125I-labeled factor IX.

Authors:  S P Bajaj; S I Rapaport; W A Russell
Journal:  Biochemistry       Date:  1983-08-16       Impact factor: 3.162

4.  Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine.

Authors:  P A von dem Borne; L O Mosnier; G Tans; J C Meijers; B N Bouma
Journal:  Thromb Haemost       Date:  1997-08       Impact factor: 5.249

5.  A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets.

Authors:  Tara N Miller; Dipali Sinha; T Regan Baird; Peter N Walsh
Journal:  Biochemistry       Date:  2007-11-17       Impact factor: 3.162

Review 6.  Structural and functional features of factor XI.

Authors:  D Gailani; S B Smith
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

7.  Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis.

Authors:  Erik I Tucker; David Gailani; Sawan Hurst; Qiufang Cheng; Stephen R Hanson; András Gruber
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

8.  Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation.

Authors:  Stephen B Smith; Ingrid M Verhamme; Mao-fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2008-01-11       Impact factor: 5.157

9.  Three residues at the interface of factor XI (FXI) monomers augment covalent dimerization of FXI.

Authors:  M Zucker; A Zivelin; M Landau; N Rosenberg; U Seligsohn
Journal:  J Thromb Haemost       Date:  2009-06       Impact factor: 5.824

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  78 in total

Review 1.  New insights into modulation of thrombin formation.

Authors:  Henri M H Spronk; Julian I Borissoff; Hugo ten Cate
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

2.  Spontaneous proton transfer to a conserved intein residue determines on-pathway protein splicing.

Authors:  Brian Pereira; Philip T Shemella; Gil Amitai; Georges Belfort; Saroj K Nayak; Marlene Belfort
Journal:  J Mol Biol       Date:  2010-12-23       Impact factor: 5.469

Review 3.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

4.  Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Authors:  Rami A Al-Horani; David Gailani; Umesh R Desai
Journal:  Thromb Res       Date:  2015-04-22       Impact factor: 3.944

Review 5.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

Review 6.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

7.  Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate.

Authors:  Patricia H Alvarenga; Xueqing Xu; Fabiano Oliveira; Andrezza C Chagas; Clarissa R Nascimento; Ivo M B Francischetti; Maria A Juliano; Luiz Juliano; Julio Scharfstein; Jesus G Valenzuela; José M C Ribeiro; John F Andersen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

8.  Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site.

Authors:  Rajesh Karuturi; Rami A Al-Horani; Shrenik C Mehta; David Gailani; Umesh R Desai
Journal:  J Med Chem       Date:  2013-03-18       Impact factor: 7.446

Review 9.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

10.  F11 rs2289252T and rs2036914C Polymorphisms Increase the Activity of Factor XI in Post-trauma Patients with Fractures Despite Thromboprophylaxis.

Authors:  Nan Song; Ai-Xian Tian; Jian-Min Zhang; Hong-Qiang Jiang; Jia-Cheng Zang; Xin-Long Ma
Journal:  Orthop Surg       Date:  2016-08       Impact factor: 2.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.